ID   PEO23
AC   CVCL_2689
SY   PE023
DR   EFO; EFO_0005447
DR   ArrayExpress; E-MTAB-691
DR   cancercelllines; CVCL_2689
DR   CancerTools; 151677
DR   Cell_Model_Passport; SIDM01418
DR   ECACC; 10032313
DR   GEO; GSM459857
DR   GEO; GSM2475001
DR   GEO; GSM4973224
DR   GEO; GSM4973230
DR   GEO; GSM4973236
DR   GEO; GSM4973242
DR   GEO; GSM4973254
DR   GEO; GSM4973266
DR   GEO; GSM4973248
DR   GEO; GSM4973260
DR   GEO; GSM4973272
DR   PRIDE; PXD020764
DR   Progenetix; CVCL_2689
DR   Wikidata; Q54947167
DR   Ximbio; 151677
RX   PubMed=3167863;
RX   PubMed=20581869;
RX   PubMed=22183581;
RX   PubMed=23415752;
RX   PubMed=25230021;
RX   PubMed=25960936;
RX   PubMed=28273451;
RX   PubMed=35028612;
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Doubling time: 120 hours (PubMed=3167863).
CC   HLA typing: A*11:01,11:01; B*35:01,35:01; C*04:01,04:01; DQB1*05:01,05:01; DRB1*01:01,01:01 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Unspecified (PubMed=25230021; PubMed=28273451).
CC   Omics: Deep proteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ECACC=10032313; PubMed=22183581; PubMed=25230021
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 15
ST   D19S433: 14,15
ST   D21S11: 27,30
ST   D2S1338: 24
ST   D3S1358: 16
ST   D5S818: 11,12 (ECACC=10032313)
ST   D5S818: 12 (PubMed=22183581; PubMed=25230021)
ST   D7S820: 9,10
ST   D8S1179: 13,14
ST   FGA: 20
ST   Penta D: 9,13
ST   Penta E: 10
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C5228; Ovarian cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2687 ! PEO14
OI   CVCL_2734 ! TO14
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 24
//
RX   PubMed=3167863;
RA   Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A.,
RA   Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.;
RT   "Characterization and properties of nine human ovarian adenocarcinoma
RT   cell lines.";
RL   Cancer Res. 48:6166-6172(1988).
//
RX   PubMed=20581869; DOI=10.1038/onc.2010.245;
RA   Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T., Temple J.,
RA   Langdon S.P., Huntsman D.G., Brenton J.D.;
RT   "Genomic analysis of genetic heterogeneity and evolution in high-grade
RT   serous ovarian carcinoma.";
RL   Oncogene 29:4905-4913(2010).
//
RX   PubMed=22183581; DOI=10.1002/path.3980;
RA   Ng C.K.Y., Cooke S.L., Howe K.L., Newman S., Xian J., Temple J.,
RA   Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D.;
RT   "The role of tandem duplicator phenotype in tumour evolution in
RT   high-grade serous ovarian cancer.";
RL   J. Pathol. 226:703-712(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=35028612; DOI=10.1016/j.xcrm.2021.100471;
RA   Huang D.-Q., Chowdhury S., Wang H., Savage S.R., Ivey R.G., Kennedy J.J.,
RA   Whiteaker J.R., Lin C.-W., Hou X.-N., Oberg A.L., Larson M.C., Eskandari N.,
RA   Delisi D.A., Gentile S., Huntoon C.J., Voytovich U.J., Shire Z.J.,
RA   Yu Q., Gygi S.P., Hoofnagle A.N., Herbert Z.T., Lorentzen T.D.,
RA   Calinawan A., Karnitz L.M., Weroha S.J., Kaufmann S.H., Zhang B.,
RA   Wang P., Birrer M.J., Paulovich A.G.;
RT   "Multiomic analysis identifies CPT1A as a potential therapeutic target
RT   in platinum-refractory, high-grade serous ovarian cancer.";
RL   Cell Rep. Med. 2:100471.1-100471.32(2021).
//